BiotechTube

Mogamulizumab (KW-0761)

Phase 1/2Completed
1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced Solid Tumors

Conditions

Advanced Solid Tumors, Metastatic Solid Tumors

Trial Timeline

Oct 1, 2014 → Feb 1, 2020

NCT ID
NCT02281409

About Mogamulizumab (KW-0761)

Mogamulizumab (KW-0761) is a phase 1/2 stage product being developed by Kyowa Kirin for Advanced Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT02281409. Target conditions include Advanced Solid Tumors, Metastatic Solid Tumors.

What happened to similar drugs?

16 of 20 similar drugs in Advanced Solid Tumors were approved

Approved (16) Terminated (1) Active (4)
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
✅letrozoleJiangsu Hengrui MedicineApproved
✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved
✅FulvestrantAstraZenecaApproved
✅Zoladex and CasodexAstraZenecaApproved
✅GefitinibAstraZenecaApproved
✅Alpelisib + FulvestrantNovartisApproved

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02281409Phase 1/2Completed

Competing Products

20 competing products in Advanced Solid Tumors

See all competitors
ProductCompanyStageHype Score
mRNA-4359ModernaPhase 2
0
mRNA-4106ModernaPhase 1
0
AK-105AkesoPhase 1
29
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
14
EXS21546BiotrialPhase 1/2
14
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
11
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
NBTXR3NanobiotixPhase 1/2
33
pegfilgrastim + LY2523355Eli LillyPhase 1
29
SON-1010Sonnet BioTherapeuticsPhase 1
27
SON-1010Sonnet BioTherapeuticsPhase 1/2
18
BT1718Bicycle TherapeuticsPhase 1/2
22
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
IMC-18F1Eli LillyPhase 1
29
Tadalafil + GemcitabineEli LillyPhase 1
29
OKI-179OnKure TherapeuticsPhase 1
19
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
26
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
24
LY3434172Eli LillyPhase 1
21